scholarly journals Polyelectrolyte-Coated Mesoporous Bioactive Glasses via Layer-by-Layer Deposition for Sustained Co-Delivery of Therapeutic Ions and Drugs

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1952
Author(s):  
Carlotta Pontremoli ◽  
Mattia Pagani ◽  
Lorenza Maddalena ◽  
Federico Carosio ◽  
Chiara Vitale-Brovarone ◽  
...  

In the field of bone regeneration, considerable attention has been addressed towards the use of mesoporous bioactive glasses (MBGs), as multifunctional therapeutic platforms for advanced medical devices. In fact, their extremely high exposed surface area and pore volume allow to load and the release of several drugs, while their framework can be enriched with specific therapeutic ions allowing to boost the tissue regeneration. However, due to the open and easily accessible mesopore structure of MBG, the release of the incorporated therapeutic molecules shows an initial burst effect leading to unsuitable release kinetics. Hence, a still open challenge in the design of drug delivery systems based on MBGs is the control of their release behavior. In this work, Layer-by-layer (LbL) deposition of polyelectrolyte multi-layers was exploited as a powerful and versatile technique for coating the surface of Cu-substituted MBG nanoparticles with innovative multifunctional drug delivery systems for co-releasing of therapeutic copper ions (exerting pro-angiogenic and anti-bacterial effects) and an anti-inflammatory drug (ibuprofen). Two different routes were investigated: in the first strategy, chitosan and alginate were assembled by forming the multi-layered surface, and, successively, ibuprofen was loaded by incipient wetness impregnation, while in the second approach, alginate was replaced by ibuprofen, introduced as polyelectrolyte layer. Zeta-potential, TGA and FT-IR spectroscopy were measured after the addition of each polyelectrolyte layer, confirming the occurrence of the stepwise deposition. In addition, the in vitro bioactivity and the ability to modulate the release of the cargo were evaluated. The polyelectrolyte coated-MBGs were proved to retain the peculiar ability to induce hydroxyapatite formation after 7 days of soaking in Simulated Body Fluid. Both copper ions and ibuprofen were co-released over time, showing a sustained release profile up to 14 days and 24 h, respectively, with a significantly lower burst release compared to the bare MBG particles.

2019 ◽  
Author(s):  
Sanobar Khan ◽  
James McCabe ◽  
Kathryn Hill ◽  
Paul Beales

<p>The anticipated benefits of nano-formulations for drug delivery are well known: for nanomedicines to achieve this potential, new materials are required with predictive and tuneable properties. Excretion of excipients following delivery is advantageous to minimise the possibility of adverse effects; biodegradability to non-toxic products is therefore desirable. With this in mind, we aim to develop tuneable hybrid lipid-block copolymer vesicle formulations where the hydrophilic polymer block is polyethylene glycol (PEG), which has accepted biocompatibility, and the hydrophobic block of the polymer is biodegradable: polycaprolactone (PCL) or polylactide (PLA). We investigate five different block copolymers for the formation of 1:1 phospholipid:polymer hybrid vesicles, compare their properties to the appropriate unitary liposome (POPC) and polymersome systems and assess their potential for future development as nanomedicine formulations. The PEG-PCL polymers under investigation do not form polymersomes and exhibit poor colloidal and/or encapsulation stability in hybrid formulations with lipids. The properties of PEG-PLA hybrid vesicles are found to be more encouraging: they have much enhanced passive loading of a hydrophilic small molecule (carboxyfluorescein) compared to their respective polymersomes and exhibit more favourable release kinetics in the presence of serum compared to the liposome. Significantly, burst release from hybrid vesicles can be substantially reduced by making the polymer components of the hybrid vesicle a mixture containing 10 mol% of PEG<sub>16</sub>-PLA<sub>25</sub> that is intermediate in size between the phospholipid and larger PEG<sub>45</sub>-PLA<sub>54</sub> components. We conclude that hybrid lipid/PEG-PLA vesicles warrant further assessment and development as candidate drug delivery systems.</p>


2019 ◽  
Author(s):  
Sanobar Khan ◽  
James McCabe ◽  
Kathryn Hill ◽  
Paul Beales

<p>The anticipated benefits of nano-formulations for drug delivery are well known: for nanomedicines to achieve this potential, new materials are required with predictive and tuneable properties. Excretion of excipients following delivery is advantageous to minimise the possibility of adverse effects; biodegradability to non-toxic products is therefore desirable. With this in mind, we aim to develop tuneable hybrid lipid-block copolymer vesicle formulations where the hydrophilic polymer block is polyethylene glycol (PEG), which has accepted biocompatibility, and the hydrophobic block of the polymer is biodegradable: polycaprolactone (PCL) or polylactide (PLA). We investigate five different block copolymers for the formation of 1:1 phospholipid:polymer hybrid vesicles, compare their properties to the appropriate unitary liposome (POPC) and polymersome systems and assess their potential for future development as nanomedicine formulations. The PEG-PCL polymers under investigation do not form polymersomes and exhibit poor colloidal and/or encapsulation stability in hybrid formulations with lipids. The properties of PEG-PLA hybrid vesicles are found to be more encouraging: they have much enhanced passive loading of a hydrophilic small molecule (carboxyfluorescein) compared to their respective polymersomes and exhibit more favourable release kinetics in the presence of serum compared to the liposome. Significantly, burst release from hybrid vesicles can be substantially reduced by making the polymer components of the hybrid vesicle a mixture containing 10 mol% of PEG<sub>16</sub>-PLA<sub>25</sub> that is intermediate in size between the phospholipid and larger PEG<sub>45</sub>-PLA<sub>54</sub> components. We conclude that hybrid lipid/PEG-PLA vesicles warrant further assessment and development as candidate drug delivery systems.</p>


Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 460
Author(s):  
Minja Mladenović ◽  
Ibrahim Morgan ◽  
Nebojša Ilić ◽  
Mohamad Saoud ◽  
Marija V. Pergal ◽  
...  

Ruthenium complexes are attracting interest in cancer treatment due to their potent cytotoxic activity. However, as their high toxicity may also affect healthy tissues, efficient and selective drug delivery systems to tumour tissues are needed. Our study focuses on the construction of such drug delivery systems for the delivery of cytotoxic Ru(II) complexes upon exposure to a weakly acidic environment of tumours. As nanocarriers, mesoporous silica nanoparticles (MSN) are utilized, whose surface is functionalized with two types of ligands, (2-thienylmethyl)hydrazine hydrochloride (H1) and (5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)hydrazine (H2), which were attached to MSN through a pH-responsive hydrazone linkage. Further coordination to ruthenium(II) center yielded two types of nanomaterials MSN-H1[Ru] and MSN-H2[Ru]. Spectrophotometric measurements of the drug release kinetics at different pH (5.0, 6.0 and 7.4) confirm the enhanced release of Ru(II) complexes at lower pH values, which is further supported by inductively coupled plasma optical emission spectrometry (ICP-OES) measurements. Furthermore, the cytotoxicity effect of the released metallotherapeutics is evaluated in vitro on metastatic B16F1 melanoma cells and enhanced cancer cell-killing efficacy is demonstrated upon exposure of the nanomaterials to weakly acidic conditions. The obtained results showcase the promising capabilities of the designed MSN nanocarriers for the pH-responsive delivery of metallotherapeutics and targeted treatment of cancer.


Pharmaceutics ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 242 ◽  
Author(s):  
Monica Terracciano ◽  
Luca De Stefano ◽  
Ilaria Rea

Diatom microalgae are the most outstanding natural source of porous silica. The diatom cell is enclosed in a three-dimensional (3-D) ordered nanopatterned silica cell wall, called frustule. The unique properties of the diatom frustule, including high specific surface area, thermal stability, biocompatibility, and tailorable surface chemistry, make diatoms really promising for biomedical applications. Moreover, they are easy to cultivate in an artificial environment and there is a large availability of diatom frustules as fossil material (diatomite) in several areas of the world. For all these reasons, diatoms are an intriguing alternative to synthetic materials for the development of low-cost drug delivery systems. This review article focuses on the possible use of diatom-derived silica as drug carrier systems. The functionalization strategies of diatom micro/nanoparticles for improving their biophysical properties, such as cellular internalization and drug loading/release kinetics, are described. In addition, the realization of hybrid diatom-based devices with advanced properties for theranostics and targeted or augmented drug delivery applications is also discussed.


2010 ◽  
Vol 142 (2) ◽  
pp. 221-228 ◽  
Author(s):  
Ferdinand Brandl ◽  
Fritz Kastner ◽  
Ruth M. Gschwind ◽  
Torsten Blunk ◽  
Jörg Teßmar ◽  
...  

2019 ◽  
Vol 24 (42) ◽  
pp. 5039-5048 ◽  
Author(s):  
Sabna Kotta ◽  
Anroop Nair ◽  
Nimer Alsabeelah

Background: 3D printing technology is a new chapter in pharmaceutical manufacturing and has gained vast interest in the recent past as it offers significant advantages over traditional pharmaceutical processes. Advances in technologies can lead to the design of suitable 3D printing device capable of producing formulations with intended drug release. Methods: This review summarizes the applications of 3D printing technology in various drug delivery systems. The applications are well arranged in different sections like uses in personalized drug dosing, complex drugrelease profiles, personalized topical treatment devices, novel dosage forms and drug delivery devices and 3D printed polypills. Results: This niche technology seems to be a transformative tool with more flexibility in pharmaceutical manufacturing. Typically, 3D printing is a layer-by-layer process having the ability to fabricate 3D formulations by depositing the product components by digital control. This additive manufacturing process can provide tailored and individualized dosing for treatment of patients different backgrounds with varied customs and metabolism pattern. In addition, this printing technology has the capacity for dispensing low volumes with accuracy along with accurate spatial control for customized drug delivery. After the FDA approval of first 3D printed tablet Spritam, the 3D printing technology is extensively explored in the arena of drug delivery. Conclusion: There is enormous scope for this promising technology in designing various delivery systems and provides customized patient-compatible formulations with polypills. The future of this technology will rely on its prospective to provide 3D printing systems capable of manufacturing personalized doses. In nutshell, the 3D approach is likely to revolutionize drug delivery systems to a new level, though need time to evolve.


Polymers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1742 ◽  
Author(s):  
Olga Cegielska ◽  
Paweł Sajkiewicz

Each year, new glaucoma drug delivery systems are developed. Due to the chronic nature of the disease, it requires the inconvenient daily administration of medications. As a result of their elution from the eye surface and penetration to the bloodstream through undesired permeation routes, the bioavailability of active compounds is low, and systemic side effects occur. Despite numerous publications on glaucoma drug carriers of controlled drug release kinetics, only part of them consider drug permeation routes and, thus, carriers’ location, as an important factor affecting drug delivery. In this paper, we try to demonstrate the importance of the delivery proximal to glaucoma drug targets. The targeted delivery can significantly improve drug bioavailability, reduce side effects, and increase patients’ compliance compared to both commercial and scientifically developed formulations that can spread over the eye surface or stay in contact with conjunctival sac. We present a selection of glaucoma drug carriers intended to be placed on cornea or injected into the aqueous humor and that have been made by advanced materials using hi-tech forming methods, allowing for effective and convenient sustained antiglaucoma drug delivery.


2017 ◽  
Vol 121 (48) ◽  
pp. 26833-26839 ◽  
Author(s):  
Thierry Azaïs ◽  
Guillaume Laurent ◽  
Kuldeep Panesar ◽  
Andreï Nossov ◽  
Flavien Guenneau ◽  
...  

2018 ◽  
Vol 5 (7) ◽  
pp. 180320 ◽  
Author(s):  
Duanhua Cai ◽  
Jingqian Fan ◽  
Shibin Wang ◽  
Ruimin Long ◽  
Xia Zhou ◽  
...  

Layer-by-layer (LbL) self-assembly is the technology used in intermolecular static electricity, hydrogen bonds, covalent bonds and other polymer interactions during film assembling. This technology has been widely studied in the drug carrier field. Given their use in drug delivery systems, the biocompatibility of these potential compounds should be addressed. In this work, the primary biocompatibility of poly(lactide-co-glycolide)-(poly-L-orithine/fucoidan) [PLGA-(PLO/fucoidan)] core–shell nanoparticles (NPs) was investigated. Atomic force microscopy revealed the PLGA-(PLO/Fucoidan) 4 NPs to be spherical, with a uniform size distribution and a smooth surface, and the NPs were stable in physiological saline. The residual amount of methylene chloride was further determined by headspace gas chromatography, in which the organic solvent can be volatilized during preparation. Furthermore, cell viability, acridine orange/ethidium bromide staining, haemolysis and mouse systemic toxicity were all assessed to show that PLGA-(PLO/fucoidan) 4 NPs were biocompatible with cells and mice. Therefore, these NPs are expected to have potential applications in future drug delivery systems.


Sign in / Sign up

Export Citation Format

Share Document